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ABSTRACT

EFFICACY OF 180 VS. 360 DEGREES OF SELECTIVE LASER TRABECULOPLASTY ON LOWERING
INTRAOCULAR PRESSURE. Robert H. McGlynn (Sponsored by M. Bruce Shields). Department of
Ophthalmology, Yale University, School of Medicine, New Haven, CT
The purpose of this study was to determine if the application of 360° of selective laser trabeculoplasty
(SLT) to the trabecular meshwork (TM) is more effective than 180° in the lowering of intraocular pressure (IOP)
in glaucoma.

This issue was addressed in the form of a retrospective chart review of patients treated

consecutively with SLT for primary open angle glaucoma, pseudoexfoliation glaucoma or ocular hypertension.
Patients were treated with either 180° of SLT by Dr. Wand or 360° by Dr. Martone using a 532nm, Q-switched,
frequency doubled Nd:Yag laser. Only the initial treatment with SLT of a given eye was analyzed. There were
108 patients per group. Patient age, type of glaucoma, history of previous argon laser trabeculoplasty (ALT),
number of medications, lens status and visual acuity pre-and post-treatment and the number and power of laser
spots were compared between the treatment groups. The mean IOP from three consecutive visits prior to
treatment was compared with post-operative IOPs measured at 1 hour, 6 weeks, and 3 months. Patients were
classified as responders if the three month postoperative IOP was reduced by more than or equal to 3 mmHg
compared to baseline.
At three months post-op the 360° group had a response rate of 60% and a mean IOP drop of 3.6
mmHg (17.8%). The 180° group had a response rate of 29% with a mean IOP drop of 1.5 mmHg (7.5%). The
number of pre- and post-treatment medications, eye treated, gender, phakic status, number of spots delivered and
pre-op IOP were equivalent for the two study groups. The 180° group subjects had more overall energy delivered
during treatment and had had previous ALT more frequently than the 360° group. The 180° group also was
significantly older and was less likely to have non-open angle glaucoma.
This study suggests that with a 2.1 mmHg greater drop in IOP and 31% greater response rate at three
months post-op 360 degrees of SLT is more effective in lowering intraocular pressure than 180 degrees.
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INTRODUCTION

Argon Laser Trabeculoplasty
Histopathology and Mechanism
Argon Laser Trabeculoplasty (ALT) was shown by Wise and Witter to be an effective
treatment for lowering intraocular pressure (IOP) open angle glaucoma (OAG) in 1979 (1).
ALT employs the application of argon laser burns to the trabecular meshwork (TM) in the
anterior chamber angle of the eye. These burns cause coagulative damage to uveoscleral
meshwork, disruption of the trabecular beams and heat-induced damaged to surrounding
collagen fibers (2). The precise mechanism of action is unknown but one theory, known as
the mechanical theory, is that the thermal energy causes coagulation and, hence, contraction of
the areas of application. This contraction causes shrinkage of the inner TM ring applying
traction on the intervening meshwork and Schlemm’s canal. The traction causes separation of
the trabecular sheets and prevents the collapse of Schlemm’s canal, therefore facilitating
outflow of aqueous humor and lowering IOP. Similar histopathological changes in the
ultrastructure of the TM as those produced by ALT have been documented after the
application of 1064 nm neodymium:yittrium-aluminum-garnet (Nd:YAG) and diode lasers
(3,4). Another theory, the cellular theory, postulates that ALT causes increases in both cell
division (5) and phagocytic activity (6) in the trabecular endothelial cells. This is thought to
cause clearing of debris from the trabecular meshwork as well as stimulate growth of healthy
trabecular tissue, thus facilitating aqueous outflow. Furthermore, ALT has been shown to
induce expression and secretion of IL-1 and TNFalpha (7). This in turn leads to increased
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expression of stromelysin in trabecular cells which plays an important role in remodeling of
the trabecular extracellular matrix and increasing aqueous outflow.

Clinical Efficacy
ALT was shown in the Glaucoma Laser Trial (GLT) to produce lower IOP, better
visual acuity and better optic disc status in treated eyes when compared to eyes treated
medically when employed as the initial treatment of glaucoma (8). In the seven year follow-up
of the GLT study initial treatment with ALT was again found to be as, if not more, efficacious
than initial medical treatment of glaucoma with an average IOP reduction of 7-10 mmHg (9).
That IOP reduction was 1.2 mmHg greater than that demonstrated by the primary medical
treatment group. Despite these findings ALT is most commonly used after medical options
have been explored without resulting in adequate IOP control in hopes of postponing or
eliminating the need for filtering or cyclodestructive surgery. While ALT has proved to be an
effective treatment, long term failure of IOP control is common. One study reported that
ALT controlled IOP in one-third of patients after a five year follow-up (10). Defining success
of treatment as a 3 mmHg decrease in IOP or more, another study found that 21% of subjects
treated with ALT were successes after five years (11).

The failure of IOP control is

hypothesized to be due to destruction of the uveoscleral meshwork from thermal damage and
membrane formation from migrating endothelial cells over the TM in between laser
applications (12, 13). In addition to long-term treatment failure, ALT can also produce
significant side effects in treated individuals. These side effects include post-op IOP spikes,
iritis and peripheral anterior synechiae (14, 15).

The amount of energy delivered during

treatment correlated with the incidence of these side-effects but did not effect the long-term

reduction in IOP (16, 17).
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Seeking to reduce the frequency of these side-effects led

investigators to attempt to lower the total amount of energy delivered to the TM without
losing efficacy of the treatment.

Selective Laser Trabeculoplasty
Selective Thermolysis
Selective Laser Trabeculoplasty (SLT) is a newer technique that uses an Nd:YAG laser
to selectively target pigmented trabecular cells without causing widespread thermal damage to
the trabecular meshwork. This technique was developed by Latina and Park in 1995 by
applying lasers pulses of various frequencies, duration and power to a mixed cell culture of
pigmented and non-pigmented TM cells (18).

They found that with lasers capable of pulses

in the sub-microsecond range it was possible to define a range of energy pulses in which
pigmented TM cells could be selectively damaged and killed while leaving adjacent nonpigmented TM cells unharmed. The theory upon which SLT is based and which makes this
selective killing possible is called selective thermolysis. The brevity of the laser pulses is critical
to produce selective thermolysis because in order to specifically target pigmented TM
endothelial cells the pulse duration must be shorter than the thermal relaxation time of
melanin.

Thermal relaxation is the time required for a chromophore to convert

electromagnetic energy into thermal energy.

At pulse durations less than the thermal

relaxation time, energy is deposited in the melanin granules faster than it can diffuse. The
thermal energy is therefore limited to the pigmented granules in the TM endothelial cells with
very little dissipated to surrounding structures, limiting their damage.
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The thermal relaxation time of melanin is approximately 1 μsec explaining why pulse
durations below this threshold allowed for selective targeting. When cultures irradiated using a
low energy, q-switched, frequency doubled Nd:YAG laser emitting at 523 nm in 10 nsec pulses
were examined the damage was strictly limited to lysosomes containing pigment granules. This
was seen as fractured melanin granules and ruptured lysosomal membranes on transmission
electron microscopy. At pulses that approached this threshold, such as the 1 μsec pulses of
the pulsed dye laser used in this study, damage was seen to subcellular organelles surrounding
the pigment granules in addition to the granules themselves. This gave evidence of the
importance of thermal diffusion in the production of collateral damage to surrounding
structures. At the light microscopy level, the damage induced by these two lasers was so subtle
that it was difficult for the investigators to distinguish irradiated areas by phase contrast
microscopy. Using stains to identify compromised cells they found non-pigmented cells
remained viable even when all of their adjacent pigmented cells had been killed. Cultures
irradiated with longer pulse durations at energies above the threshold that caused cell damage
showed complete vaporization of both pigmented and non-pigmented cells at the burn sites.
The q-switched, frequency doubled Nd:YAG laser application delivers about 0.6 – 1.0
mJ per pulse which is 1% of what traditional ALT delivers at 60-100 mJ per pulse. SLT is able
to be applied over a much larger area because spatial targeting is unnecessary. SLT is usually
applied with a spot size of 400 μm versus the 50 μm spot size in ALT. Coupling the lower
amount of energy delivered in SLT with a larger spot size over which this energy is applied
leads to a far lower fluency (energy/area) in SLT when compared with ALT. Due to the low
fluency required together with the approximately 1mm tissue penetration and relative
transparency of collagen in the trabecular beams to 523 nm light, it was hypothesized that the
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results found on the two dimensional cell cultures could be applied to the three dimensional
trabecular meshwork with similar selectivity.

Histopathology
Microscopic studies have subsequently shown the selectivity of SLT when applied to
human eyes. Scanning electron microscopy (SEM) performed on the TM after application of
ALT showed crater formation with evidence of coagulative damage at the base and edges (2).
This was seen in the form of whitening and bleb formation. There was also disruption of the
collagen scaffolding and trabecular beams with debris from these structures in the adjacent
intratrabecular spaces. SEM on SLT treated specimens, on the other hand, showed minimal
mechanical disruption of the collagen scaffolding and trabecular beams with no evidence of
crater formation or coagulative damage. Transmission electron microscopy (TEM) on ALT
specimens showed similar disruption of trabecular beams and collagen scaffolding immediately
surrounding the laser lesions. Additionally, trabecular endothelial cells were found to be
disrupted with many of them appearing to be detached from the trabecular beams. The
pigment granules within these cells were rounded and intact. SLT specimens examined with
TEM showed no disruption of the TM which was lined with a continuous layer of trabecular
endothelial cells. In contrast to the ALT treated specimens many of the intracytoplasmic
pigment granules in the SLT treated specimens were cracked and fragmented as Latina and
Park (18) found in cell culture. This is precisely where SLT is designed to interact. Many of
these endothelial cells were also vacuolated. The Kramer et al. study (2) study involved ALT
using the standard energy delivery levels of 60 – 100 mJ/pulse. A more recent study examined
the effect of lower energy ALT (46 mJ/pulse) versus standard SLT application to the TM of
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eyes one to five days prior to enucleation for malignant melanoma of the choroid (19). This
study found that both treatments caused disruption of the trabecular beams and desquamation
of endothelial cells but that the extent of this damage was less after SLT. They also found that
long-spacing collagen was better preserved after SLT.

Mechanism of Action
The lack of coagulative damage induced by ALT suggests that any IOP reduction
caused by SLT is due to the selective killing of pigmented trabecular meshwork cells and the
biologic response that ensues. Multiple biologic reactions have been documented and all of
them can be at least partially attributed to the induced expression of various cytokines after
SLT.

Cytokine Production and Endothelial Cell Permeability

As with ALT, SLT has been shown to increase expression of IL-1 and TNF-alpha with
the addition of IL-8 (20). These cytokines are important in the recruitment of macrophages
which may help to clear debris from the TM and facilitate aqueous outflow. A study by
Alvarado et al. (20) found that SLT applied to trabecular meshwork cells in culture produces
increased levels of these cytokines in the culture medium.

When endothelial cells from the

TM and Schlemm’s canal were incubated with this culture medium it was found that it
significantly altered their genetic expression. The increase in cytokine activity and altered
expression of genes occurs simultaneously with an increased rate of conductivity of aqueous
humor across monolayers of these two cell types.

This increased conductivity is also

reproducible by administering exogenous IL-1 alpha and beta, TNF-alpha and IL-8 to these
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cellular monolayers. This is an important finding because the endothelial cells of Schlemm’s
canal form the last barrier of the outflow tract and exert important control over how much
aqueous humor leaves the eye and enters the venous circulation. If SLT produces the same
four-fold increase in conductivity in Schlemm’s canal endothelial cells in vivo that it produces
in vitro it could explain much of the IOP reduction seen clinically.

Extracellular Matrix Remodeling

The TM extra-cellular matrix has been shown to be both increased and modified in
primary open angle glaucoma (POAG) (21, 22). This is thought to be another pivotal factor in
the outflow resistance and elevated IOP in this condition. The normal turnover of the TM
extra-cellular matrix is partially governed by the activity of metalloproteinases (MMPs) (23, 24).
The activity of MMPs, in turn, is increased by the cytokines IL-1 and TNF-alpha (25, 26, 27).
The ratio of MMP concentration to the concentration of their inhibitors’ is also increased by
these cytokines. These inhibitors are called tissue inhibitors of metalloproteinases, or TIMPs.
MMP-2 is the predominant gelatinase in the aqueous humor and its inhibitor, TIMP-2, is up
regulated in POAG (28). This imbalanced ratio of MMP-2 to TIMP-2 is thought to be
responsible for the decreased collagenase activity of aqueous humor from POAG eyes in vitro
(29). The increased expression of cytokines after SLT could be influencing the ratio between
these two factors and inducing remodeling of the extracellular matrix in the TM. This finding
is similar to the finding of increased expression of stromalysin, another MMP, due to increased
IL-1 and TNF-alpha activity after ALT (27).

Endothelial Cell Repopulation
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Another one of the main factors that is thought to contribute to the etiology of POAG
is the relative dearth of endothelial cells in the TM when compared to healthy controls. The
endothelial cells in the TM and Schlemm’s canal undergo mechanical deformation due to
stretching when IOP is elevated (30). This mechanical stretching has been shown to induce
various changes in signal transduction, genetic expression and permeability in the anterior
segment of the human eye (31, 32). Among the up regulated genes are PIP 5K1C, VIP,
tropomodulin, and MMP2 which are known to influence outflow resistance.

A similar

increase in MMP-2 as well as a decrease in TIMP-2 in TM endothelial cells due to mechanical
stretch have been found in other studies (33). This increased expression of MMP-2 was
shown to correlate with the ability of eyes challenged with increased flow rates to restore IOP
to normal levels after a couple of days (34). This effect was hypothesized to be a result of
pruning of the TM extracellular matrix and subsequent reduction in outflow resistance. The
decreased cellularity of the TM in POAG when compared to age matched normal controls
(35) may lead to increased IOP due to an inability of the present cell population to generate
equivalent levels of these factors in response to a given IOP as would be produced by a
normally populated TM. This decreased cellularity of TM endothelial cells may also contribute
to elevated IOP by not being able to produce sufficient concentrations of cytokines to
adequately alter the permeability of the Schlemm’s canal’s endothelial cells. The importance of
this is that laser treatments have been shown to increase cell division in the TM (5). This is
likely to be at least partially due to the ability of cytokines to act as growth factors for TM
endothelial cells. SLT, by inducing cytokine expression, may be triggering a repopulation of
the TM endothelial cells and therefore restoring the ability of this cell population to adequately
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respond to increases in IOP. The new population of TM cells could then secrete factors
important in the regulation of the permeability of Schlemm’s canal endothelial cells and in the
proper turnover in the TM extracellular matrix.
There is one more piece of evidence that supports the importance of the biological
response induced by SLT in lowering IOP. This evidence comes from a study that found that
untreated eyes contra lateral to SLT treated eyes exhibit a statistically significant pressure
reduction (36). This study found a 9.7% IOP reduction in these untreated eyes at 6 months.
A mechanical mode of action is ruled out in the contra lateral eye as the laser was not applied
there. This suggests that the inflammatory cascade induced in the treated eye has some
crossover effect in the untreated eye.
In summary, there is strong evidence that SLT is inducing biological responses in the
TM that are responsible for IOP reduction. These mechanisms are the increased expression
of cytokines, increased permeability of the endothelial cells in the TM and Schlemm’s canal,
remodeling of the extracellular matrix of the TM and repopulation of TM endothelial cells. All
of these mechanisms influence each other and the induction of cytokine expression plays a
potential role in modulating all of them.

Clinical Efficacy
Clinical trials thus far conducted have shown reasonable response rates, effective IOP
reduction and minimal side effects. The first study to look at the clinical applicability of this
procedure was published in 1998 (36).

This study included a total of 53 eyes with

uncontrolled open-angle glaucoma (OAG) treated with 180° degrees of SLT followed for 26
weeks. They found that 70% of the treated subjects had a reduction of IOP of greater than 3
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mmHg with an average drop of 4.6 mmHg (18.7%) after 26 weeks. The magnitude of this
reduction was uninfluenced by previous treatment with ALT.

This demonstrated that

effective, clinically significant IOP reduction could be accomplished without inflicting
coagulative damage to the trabecular meshwork. Interestingly, this study also found that there
was a statistically significant, albeit less extensive, 9% reduction in the IOP of the fellow
untreated eyes in these subjects. Subsequently there have been many other studies published
addressing the clinical efficacy of SLT. These results are summarized in Table 1. Overall, the
response rate to SLT was 63.1% with a range from 14-88% at a mean follow-up time of 19.4
months. The mean decrease in IOP was 6.18 mmHg (2.1-10.6) with a percentage decrease of
26.0% (11.9-39.9). When only the studies that reported follow-up periods of longer than one
year are included in these figures the mean response rate was 60.2% with a mean IOP drop of
5.7 mmHg (2.1-8.6) reflecting a 24.0% drop (11.9-35.1). These are significant responses and
the majority are either similar to or better than outcomes reported for ALT (9, 10, 11).

Sample
Latina et al.
(36)
Lanzetta et al.
(37)
Kim et al. (38)
Gracner (39)
Gracner (40)

Melamed et al.
(41)
Cvenkel (42)
Lai et al. (43)
Best et al. (44)

50 POAG
3 PG
8 POAG

Table 1
Summary of studies reporting efficacy of SLT
Baseline
Follow-up
Response Rate
IOP
(mmHg)
24.6
26 weeks
70%
26.6

6 weeks

16 POAG
50 POAG
10 CG
10 POAG

24.4
22.5
23.6
22.8

1 year
6 months
12 months
13.5 months

45 POAG
(primary Tx)
44 POAG
29 POAG/OHT
269 POAG/LTG/OHT

25.5

18 months

25.6
26.8
22.7

1 year
5 years
2 years

IOP Reduction
(mmHg)
4.6 (18.7%)
10.6 (39.9%)

88%
64%
78%

4.9 (20.2%)
5.1 (22.5%)
7.4 (31.4)
8.0 (35.1%)
7.7 (30%)

62%

4.7 (18.6%)
8.6 (32%)
2.7 (12.1%)
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Table 1 continued
Kano et al.
67 POAG
(45)
Hodge et al.
72 POAG/PXG/PG
(46)
Kajiya et al.
17 POAG
(47)
Jindra (48)
283 POAG
(primary Tx)
43 POAG
(repeat Tx)
Song et al. (58) 94
POAG/PXG/PG/LTG

22.4

6 months

68.7% at 1 mo.

4.4 ( 19.6%)

23.8

1 year

59.7%

5.8 (24.4%)

22.8

6 months

6.7 (29.4%)

21.1

4.8 months

7.4 (35%)

23.7

3.5 months

8.2 (35%)

17.6
68.7+

14.5 months

14%

2.1 (11.9%)

Table 1. Summary of studies reporting efficacy of SLT. Abbreviations: SLT, selective laser
trabeculoplasty; IOP, intraocular pressure; POAG, primary open angle glaucoma; CG, capsular
glaucoma; OHT, ocular hypertension; LTG, low-tension glaucoma; PXG, pseudoexfoliation glaucoma;
PG, pigmentary glaucoma.
SLT vs. ALT

Clinical trials that have compared ALT to SLT have also shown that the two
treatments have similar efficacy. A study comparing 154 patients treated with ALT to 41
patients treated with SLT, all on maximal medical therapy, found that there was no significant
difference in success of treatment at an average follow-up time of 34.4 months (11). This
equivalence was found two separate criteria for success: one was and IOP reduction of greater
than 20% of baseline IOP (P=0.12) and the second was an IOP reduction of greater than 3
mmHg (p=0.20). There was no significant difference in the percentage reductions in IOP with
27.1% and 23.5% decreases in the SLT and ALT groups respectively (P=0.75). Other studies
comparing SLT to ALT are summarized in table 2. Briefly, over an average follow-up period
of 5.6 months these three studies reported an average IOP reduction of 4.8 mmHg (2.85-6.9)
for SLT and 5.0 mmHg (2.63-6.6) for ALT. This corresponded to percentage reductions of
20.9% (13.4-29.2) for SLT and 22.0% (13.0-29.2) for ALT. None of the IOP reductions
differed significantly in any of the three studies. This establishes that SLT is a viable treatment
alternative to ALT. In fact, it may offer some advantages such as a decreased incidence of
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complications and a potential for repeatability that make it a more attractive treatment
option when compared to ALT. These issues will be discussed in greater detail below.

Martinez de
la Casa et al.
(49)
Damji et al.
(50)
Popiela et al.
(51)
Pirnazar et al.
(52)
Tabak et al.
(53)

Table 2
Summary of studies comparing efficacy of SLT vs. ALT
SLT Sample
ALT Sample Follow-up
SLT IOP
ALT IOP
Reduction
Reduction
20 POAG
20 POAG
6 months
5.4 mmHg
4.6 mmHg
(22.2%)
(19.5%)
18 POAG

18 POAG

6 months

27 POAG

27 POAG

3 months

30 POAG

27 POAG

12 months

22 patients

17 patients

4 weeks

5.0 mmHg
(21.9%)
2.85 mmHg
(13.4%)
6.9 mmHg
(29.2%)
3.84 mmHg
(17.7%)

4.8 mmHg
(21.3%)
2.63 mmHg
(13.0%)
6.6 mmHg
(29.2%)
6.5 mmHg
(26.8%)

P-Value
0.81
0.97
0.84
0.86
Not
significant

Table 2. Summary of studies comparing efficacy of SLT vs. ALT. Abbreviations: SLT, selective laser
trabeculoplasty; ALT, argon laser trabeculoplasty; IOP, intraocular pressure; POAG, primary open
angle glaucoma.
SLT After ALT

Due to the fact that SLT does not cause coagulative damage to the TM, it offers the
possibility of benefiting patients who have failed previous ALT. SLT can be applied without
causing further scarring and potential outflow obstruction as is thought to be a possible
problem with repeat ALT treatments. A study conducted examining the effect of repeat ALT
treatments on 40 eyes of 37 patients found a greater than 3 mmHg drop in IOP response rate
of 32% (54). At 1.75 years 14% of these patients continued to have successful control of IOP.
This study concluded that although it is a safe option to repeat ALT, the likelihood of success
is low.
A study that addressed the question of the relative efficacy of repeat ALT treatments
and SLT after previous ALT found that there was not significant difference between the two
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at the 5 year follow-up (11). They found that there was no difference in the response rates
when success was defined as a reduction of IOP greater than 3 mmHg (P=0.35) or greater
than 20% (P=0.21). It should be noted that 6 patients (14.6%) in the SLT group and 16
patients (10.4%) in the ALT group had previously received 180 degrees of ALT. These 22
patients were included in the no prior treatment groups during analysis. This was done with
the rationale that the treatment was a primary treatment because the surgeon treated the
previously untreated 180 degrees of the TM.

In the other studies mentioned below these

patients would have been included in the repeat treatment groups. Differing from these
findings, Damji et al. found that patients with previous failed ALT had a greater reduction in
IOP with SLT (6.8 mmHg, 29.8%) than with repeat ALT (3.6 mmHg, 16.0%) (P= 0.01) after 6
months (50).
Another study that compared pressure reduction and response rates of SLT either as
the primary laser treatment or after previous ALT found that there was no difference in IOP
reduction in these two groups (36). They reported 5.8 mmHg (23.5%) and 6.0 mmHg (24.2%)
reductions in IOP at 26 weeks in the primary SLT and previous ALT groups, respectively.
Both groups had a 3 mmHg IOP reduction response rate of 70%. Similarly, Chen et al. that
IOP reduction is independent of previous ALT treatments (55).

Repeat SLT Treatments

SLT has been shown to be as effective as ALT with less histological damage to the
trabecular meshwork. Additionally, the efficacy of SLT has been demonstrated in patients
with previous ALT. These two facts have lead to the promise of SLT being a repeatable
treatment. Repeat ALT is not favored due to the permanent changes it causes on the first
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application and the mixed findings on its long term efficacy. There is not yet much data
supporting the clinical repeatability of SLT. One study found that response rates on repeat
SLT always exceeded 50%, in some cases by a considerable amount (56). This study was
conducted on a mixed group of glaucoma patients with a mean time of 12 to 15 months
between SLT treatments. In a small sample of patients that had received a third SLT
treatment they found a 100% response rate with an average pressure reduction of 10.8 mmHg.
They also found that the degree of pressure reduction and 3 mmHg IOP reduction response
rate was positively correlated with having a baseline IOP of greater than 21 mmHg. Another
study compared 283 primary to 43 repeat SLT treatments and found that there was a 35%
reduction in IOP in both groups (48). All of these studies concur in their findings that, when
repeated, SLT is effectively lowers IOP.

SLT as Initial Therapy

The Glaucoma Laser Trial Follow-up Study established ALT as a viable first line
treatment option for POAG. Despite this it continues to be employed after medical therapy
has failed to control IOP in order to avoid the need for incisional pressure lowering surgery.
Given the equivalent efficacy of SLT and ALT, it follows that SLT may be viable option for
primary treatment of POAG as well. In fact, there have been studies that support this
hypothesis. One study examined the response of 45 eyes with either POAG or ocular
hypertension with a mean baseline IOP of 25.5 mmHg to primary treatment with SLT (41).
At 18 months follow-up the mean drop in IOP was 7.7 mmHg (30%) with 43 of the 45 eyes
responding with a greater than 20% reduction. Forty of the eyes had an IOP reduction of
greater than 5 mmHg. Another study compared 283 primary to 43 repeat SLT treatments and

15
found that there was a 35% reduction in IOP in both groups. The initial treatment group
had and IOP reduction of 7.4 mmHg from 21.1 to 13.7 mmHg. The repeat group had a drop
of 8.2 mmHg from 23.7 to 15.5 mmHg. One additional study on 29 newly diagnosed patients
randomized one eye of each patient to receive SLT and the other medical treatment (43). The
baseline IOPs were 26.8 and 26.2 mmHg in the SLT and medication groups respectively
(p=0.62). At the end of the five year follow-up the mean pressure drops were 8.6 (32.1%) and
8.7 (33.2%), respectively (P=0.95). They also had similar failure rates of therapy as defined as
an IOP of greater than 21 mmHg at five years of 17.2% and 27.6%, respectively (P=0.53).
Eight of the SLT eyes (27.6%) required medications to keep their IOP below this threshold
but the SLT group required less medications at the five year follow-up (0.46-0.55) compared to
the medications group (1.45-1.63) (P<0.001). In summary, these studies suggest that as with
ALT, SLT is an effective initial treatment for POAG.

Adverse Effects

SLT administers 1% of the energy delivered by ALT. This most likely accounts for its
relatively lower complication rate than ALT. In the Glaucoma Laser Treatment Follow-up
Study (9) 34% of subjects had an IOP rise more than 5 mmHg after treatment. Following
SLT, two studies reported incidence of IOP rises greater than 5 mmHg at 25% (41) and 11%
(36). Martinez-de-la-Casa et al. found that the degree of IOP elevation immediately following
SLT was lower than that occurring after ALT, although this difference was not significantly
different (49). This same study compared the anterior chamber reaction after SLT and ALT.
At 1 hour after treatment the SLT group had significantly less flare than the ALT group using
a laser flare meter (13.3 vs. 20.7 photons/ms, P=0.003). Alternatively, Damji et al. reported an
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increased anterior chamber reaction after SLT when considering the number of cells
observed (p<0.001) (50). Another study reported that 83% of subjects had a mild to moderate
anterior chamber reaction after SLT but that the usually decreased within 24 hours with no
persistent cases of iritis (36).
The incidence of pain after SLT has been reported at 15% of patients (36). Another
study described significantly less pain after SLT when compared to ALT (49). The GLT group
observed that 34% of patients receiving ALT had formation of peripheral anterior synechiae
(PAS) (9).

These PAS did not have any effect on pressure control, number of medications

needed or need for pressure reducing surgery. In their original clinical study Latina et al.
reported that there was no evidence of any PAS formation (36). Other possible side effects
are non-specific conjunctivitis and corneal edema but these are usually mild and transient
occurrences.

Variables Influencing Outcome of SLT

ALT has previously been shown to produce a greater IOP decrease in eyes with a
higher initial pressure (57). Studies on SLT have thus far returned mixed results. One study
from Japan found that lower baseline IOP was predictive of SLT success (45). Another study
found precisely the opposite with a greater success rate in patients with higher baseline IOP
(58). An observational case study series found increased degree of TM pigmentation has been
found to result in greater risk of complications, including post-op IOP spikes after SLT (59).
Despite this increased rate of adverse effects another study found that TMs with greater
degrees of pigment have significantly greater reductions in IOP at 7 month follow-up (55).
This study also found that patients with pseudoexfoliation have an increased response to SLT.
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The number of medications that a patient is on has also shown to have an effect on the
outcome of ALT with the presence of fewer medications producing statistically significant
better outcomes (60). This has also been found with SLT (58).
The type of medications an eye is treated with has also proved to be important in the
outcome of SLT. Eyes treated with prostaglandins have been reported to have a diminished
response to SLT. In one study there was a trend towards subjects on prostaglandins having a
higher failure rate after SLT (58). Another study found an increased percentage of patients on
prostaglandins were not responsive to SLT (Bryce A. Ford MD, personal communication,
2005). They found that 76% of responders (41/54) were taking prostaglandins, compared to
91% of non-responders (49/54) (p=0.039). This decreased response rate may in part be due
to the fact that both prostaglandins and SLT are thought to act on the aqueous outflow tract.
PGs have been shown to induce increased expression of MMP-1,-2 and -3 both in vitro and in
vivo (61). In vivo, this induction corresponded with a decreased concentration of types I, III
and IV collagen, which are some of the TM extracellular matrix substrates which the MMPs
degrade. As discussed above, SLT has been shown to act on this same pathway. The
population of MMPs may be depleted by prostaglandin treatment precluding SLT from acting
on this pathway. Another possibly redundant mechanism between these two treatments is that
they both act by recruiting inflammatory cells. Prostaglandins may be precluding the ability of
SLT to cause a cellular response. Despite the idea that steroids may interfere with the
inflammatory cascade and thus diminish the efficacy of SLT, this has proved to be either
unfounded (62) or possibly beneficial (63).

Degrees of TM Treated with SLT
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SLT has a lot of evidence supporting its use as a treatment for open angle glaucoma,
possibly as a first line treatment. This said it still remains a relatively new technique for which
the optimal amount of power delivered and extent of the trabecular meshwork that should be
treated still remains to be determined. These issues have been addressed in previous studies
although the question has not been sufficiently resolved. With ALT the amount of energy
delivered correlates with the incidence of post-op IOP spikes, iritis and peripheral anterior
synechiae although this was not thought to influence the long-term reduction in IOP (14, 15,
16). A study comparing the degrees of the TM treated with ALT showed a greater success rate
in eyes treated with 100 spots over 360 degrees (group 1, 26 eyes) when compared to eyes
treated with 50 spots over 180 degrees (group 2, 20 eyes) (64). The baseline IOP in group one
was 35.9 mmHg and 36.3 mmHg in group 2. Success was defined as a reduction of IOP to
below 22 mmHg. At 12 months group 1 and group 2 had success rates of 69% and 15%,
respectively.
Thus far there have been three studies examining the issue of the degree of the TM
that should be treated with SLT. One study by Chen et. al. found that 90 and 180 degrees of
SLT had equivalent efficacy (55). Both groups were composed of 32 eyes that were followed
up for 7 months. The baseline IOPs were 25.44 and 26.06 for the 90 and 180 degree groups,
respectively. The overall IOP reductions were 7.01 mmHg (27.6%) and 6.16 mmHg (23.6%),
respectively (P=0.21). There was no significant difference between the IOPs at 1, 4 or 7
months. There was also a similar rate of treatment failure with 15 of the 32 patients in the 90
degree group requiring repeat SLT or trabeculectomy by the 7 month follow-up and 13 of the
32 in the 180 degree group.
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The second study by Nagar et. al. compared the relative efficacies of latanoprost and
90, 180 and 360 degrees of SLT in 167 patients with either POAG or ocular hypertension (65).
There were 39, 35, 49 and 44 patients in these groups, respectively. At an average follow-up
time of 10.3 months they found that the 360 degree group had success rates of 82% (greater
than 20% reduction) and 59% (greater than 30% reduction). The success rates in the 180
degree group were 65% and 48%, as defined by these two criteria (P<0.1). While these
response rates trended towards being more efficacious with 360 degrees than 180 degrees they
did not reach statistical significance.

Furthermore they found that 360 and 180 degree

treatments had a greater response rate than 90 degrees (P<0.05), which was generally not
effective. Latanoprost had response rates of 90% and 78% which were significantly higher
than 90 (p<0.001) and 180 (P<0.02) degrees but were statistically equivalent to those of 360
degrees (P<0.5). Adverse events including, IOP spikes, transient uveitis and ocular pain were
more common in the 180 and 360 degree group compared to 90 degrees but only reached
statistical significance in a couple of instances. These instances were that ocular pain was more
common (P>0.001) and mean IOP at 1 hour was higher (P<0.05) after 360 degrees than after
90 degrees of SLT.
The last study compared 19 eyes that received 180 degrees and 17 that received 360
degrees of SLT (66). The mean baseline IOP was 20.6 mmHg in the 180 degree group and
21.7 mmHg in the 360 degree group. The mean change in IOP was 1.7 mmHg (8.3%) in the
180 degree group and 4.5 mmHg (20.7%) in the 360 degree group (p=0.15) at three months.
Of these three studies, one showed no effect due to the extent of TM treated with
SLT, another showed 360 degrees to be superior to 180 and 90 degrees and a third found a
non-significant trend of 360 degrees being more efficacious than 180 degrees. As discussed
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above, ALT had a more robust IOP response when applied over 360 degrees of the TM
than after 180 degrees. SLT and ALT have been shown to have similar response rates and
efficacy in many respects and these three studies suggest that they both have better efficacy
when more of the TM is treated, although this is not yet established. In order to address this
question we conducted a retrospective chart review of 108 patients treated with 180 degrees
versus 108 patients treated with 360 degrees of SLT.
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MATERIALS AND METHODS

Patient Selection
A retrospective chart review of patients with primary open angle glaucoma,
pseudoexfoliation glaucoma and glaucoma suspects treated with SLT was conducted. Patients
at the Hamden Eye Center were treated between January 22, 2004 and September 8, 2005 with
360 degrees of SLT by Dr. James Martone. Patients at the University of Connecticut were
treated between September 5, 2002 and August 5, 2004 with 180 degrees of SLT by Dr. Martin
Wand. Patients were selected at the discretion of these physicians for SLT because they were
felt to have IOPs above their goal pressures. Therefore patients were included who had either
failed to control IOP adequately on maximum medical therapy, opted for SLT treatment over
medical treatment or were intolerant of medications. After obtaining permission from Yale
University School of Medicine Human Investigations Committee the charts of patients treated
consecutively during these periods were reviewed and their eyes were included in the study if
they met the inclusion criteria. The inclusion criteria were: (1) eyes had to have POAG,
pseudoexfoliation glaucoma or be glaucoma suspects, (2) the eye had to have undergone its
first time treatment with SLT, (3) eyes had to have at least three pre- and post-operative IOP
measurements with the last one being at least 3 months after treatment.

Exclusion criteria

were: (1) prior treatment with SLT, (2) prior pressure lowering surgery including
trabeculectomy, cyclodestructive therapy and peripheral iridotomies, (3) inadequate preoperative data, (4) inadequate post-operative follow-up. Patients who had undergone prior
ALT were included in this study. Patient information including age, type of glaucoma, history
of previous ALT, phakic status and pre- and postoperative visual acuity and number and type
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of medications was collected. In addition, which eye was treated, the number and power of
laser spots, three consecutive pre-operative IOP measurements and two post-operative
measurements at 6 weeks and three months were collected for both eyes.

Operative Technique
Dr. Martin Wand
Patients were treated preoperatively with pilocarpine 2% and anesthetized with topical
anesthetic. SLT was applied with a Lumenis Selecta 532nm, Q-switched, frequency doubled
Nd:Yag laser with a 3 nsec pulse duration using a slit lamp delivery system, a Latina goniolens
and methylcellulose. The TM was targeted using a helium-neon targeting beam. An average
of 103 spots were delivered over 180 degrees of the TM with a spot size of 400 μm. This spot
size was adequate to irradiate the entire anteroposterior width of the TM. The energy level
was initially set at 0.8 mJ and increased in 0.1 mJ increments until small bubbles appeared. The
rest of the TM was irradiated at this energy level. The total amount of spots, the average
energy per spot and the total amount of energy delivered were recorded. Post-operatively
patients were treated with pilocarpine 2% and prednisolone. They were then treated with a
topical NSAID QID for 5 days while continuing on their prior pressure lowering medication
regimen.

Dr. James Martone
Patients were treated preoperatively with pilocarpine 2% and apraclonidine 0.5%.
They were anesthetized with topical properacaine 0.5%. SLT was applied with a Lumenis
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Selecta 532nm, Q-switched, frequency doubled Nd:Yag laser with a 3 nsec pulse duration
using a slit lamp delivery system, a goniolens and methylcellulose. The TM was targeted using
a helium-neon targeting beam. An average of 104 spots were delivered over 360 degrees of
the TM with a spot size of 400 μm. This spot size was adequate to irradiate the entire
anteroposterior width of the TM. The energy level was initially set at 0.8 mJ and increased in
0.1 mJ increments until blanching or small bubbles were observed. The energy was then
backed off 0.1 mJ and the rest of the TM was irradiated at this energy level unless blanching or
bubbling was again observed in which case the energy was lowered another 0.1mJ. The total
amount of spots, the average energy per spot and the total amount of energy delivered were
recorded. Post-operatively patients were treated with diclofenac 0.1% ophthalmic solution
QID for four days while continuing on their prior pressure lowering medication regimen.

Postoperative Follow-up
Patients were seen by their respective treated physicians at 6 weeks and 3 months postoperatively. At these visits a slit lamp examination of the anterior segment and an IOP
measurement using a Goldman applanation tonometer were performed. At the three month
follow up a follow-up visual acuity assessment was performed and the total number of
medications was recorded.

Throughout the follow-up period patients’ antiglaucoma

medications were adjusted as needed to control IOP.

Success Criteria
The primary outcome measure of this study was to compare the IOP reductions at
three months after 180 and 360 degrees of SLT. In addition to reporting mean IOP reduction
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and percentage reduction of the two groups two sets of success criteria were defined that
divided the treatments groups into responders and non-responders. These two success criteria
were 3 mmHg and 20% reductions of IOP from baseline values at three months.. Baseline
IOP was determined by averaging the three consecutive IOP measurements immediately
preceding the SLT administration. These criteria were chosen because historically they have
been the benchmarks by which success of laser trabeculoplasty treatments have been judged.

Statistical Analysis
All data was analyzed using SAS version 9.1 published by SAS Publishing Cary, NC.
Visual acuity values were transformed into a logarithmic scale prior to analysis using the
conversion chart described in table 3 (67).
Table 3
Snellen to Logarithmic Conversion Chart
LogMAR
Snellen
LogMAR
Snellen
-0.30
10
0.70
100
-0.20
12.5
0.76
114
-0.10
16
0.80
125
0.00
20
0.88
150
0.10
25
0.90
160
0.18
30
1.00
200
0.20
32
1.10
250
0.30
40
1.18
300
0.40
50
1.20
320
0.48
60
1.30
400
0.50
63
1.60
800
0.54
70
2.00
2000
0.60
80
3.00
20000

Table 3. Chart used to convert Snellen chart measurements of visual acuity into a logarithmic scale.
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RESULTS

Patient Demographics
A total of 216 eyes from 195 patients were included in the final analyses. Table 4
presents the baseline descriptive statistics of the patients in both treatment arms. Patients in
the 180° group were significantly younger than the 360° group with a mean age of 70.417 years
versus 74.296 years (P=0.0176). Distribution of gender and which eye was treated were
equivalent between both groups (P=0.0525, P=0.2760, respectively). Glaucoma type
composition of the two groups differed, with 99 patients in the 360° group and 106 patients in
the 180° group having primary open angle glaucoma (P=0.0303). The remaining patients in
these two groups were composed of either pseudo-exfoliation glaucoma or were glaucoma
suspects. A statistically equivalent number of patients had previous cataract surgery and intraocular lens placement in both groups with 28 and 32 patients (P=0.5434) in the 360° and 180°
groups, respectively. A total of 43 patients in the 180° group had received prior ALT
application which was significantly more than the 18 patients in the 360° group (P=0.0002).
Both groups had equivalent pre-operative visual acuity with means of 0.2615 and 0.2726
(P=0.7242) in the 360° and 180° groups, respectively. Both groups were on statistically
equivalent number of medications pre-operatively (P=0.6148).

See figure 1 for graphic

representation of number of medication administered to patients in both groups. Of these
medications the 180° group was on significantly more prostaglandins with 86 patients taking
them pre-operatively compared with 59 patients in the 360° group (P<0.0001).
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Table 4
Summary of patient demographics

Factor

360°

180°

comments

74.296 +/- 10.493

70.417 +/- 13.122

P=0.0176

Male
Female

37 (34.26%)
71 (65.74%)

51 (47.22%)
57 (52.78%)

P=0.0525

OD
OS

52 (48.1%)
56 (51.9%)

60 (55.6%)
48 (44.4%)

P=0.2760

POAG
PXG
GS

99 (91.7%)
7 (6.5%)
2 (1.9%)

106 (98.1%)
2 (1.9%)
0 (0%)

P=0.0303

Phakic
Psuedophakic

80 (74.07%)
28 (25.93%)

76 (70.37%)
32 (29.63%)

P=0.5434

No
Yes

88 (83.02%)
18 (16.98%)

65 (60.19%)
43 (39.81%)

P=0.0002

0.2615 +/- 0.2413

0.2726 +/- 0.2172

P=0.7242

12 (11.11%)
16 (14.81%)
29 (26.85%)
28 (25.93%)
23 (21.30%)

6 (5.56%)
19 (17.59%)
30 (27.78%)
26 (24.07%)
27 (25.00%)

P=0.6148

Age (years)
Gender
Eye
Glaucoma type

Lens Status
Previous ALT
Pre-op Visual Acuity
No. of Meds, Pre-op
0
1
2
3
≥4
Prostaglandin
Treatment

No
49 (45.37%)
21 (19.63%)
Yes
59 (54.63%)
86 (80.37%)
P<0.0001
Table 4. Summary of patient demographics. All values given +/- standard deviation. Abbreviations: OD, right
eye; OS, left eye; POAG, primary open angle glaucoma; PXG, pseudoexfoliation glaucoma; GS, glaucoma
suspect; ALT, argon laser trabeculoplasty. Visual acuity values were transformed into a logarithmic scale prior to
analysis.
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Pre-Treatment Medications
35

30

Number of Patients

25

20
360
180
15

10

5

0
0

1

2

3

≥4

Number of Medications

Figure 1. Number of intraocular pressure lowering medications patients were taking prior to treatment
with SLT in both 180 and 360 degree subgroups. There was not a statistically significant difference in
the number of medications the two treatment groups were receiving (P=0.6148).

Post-operative results are summarized in table 5. Both treatment arms received an
equivalent number of SLT spots (P=0.7695). The spots applied to the 180° group were
significantly more powerful than the 360° group and therefore they received more overall
power (107.38 mJ vs. 91.406 mJ, P<0.0001). Post-operatively both groups had an equivalent
decrease in the mean number of medications administered (-0.009 vs. -0.114, 360° vs. 180°
respectively, P=0.2499) and were therefore still on comparable numbers of medications
(P=0.3620). Both groups also had a statistically equivalent reduction in visual acuity with a
reduction of 0.0164 in the 360° group and 0.0069 in the 180° group (P=0.6455).
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Table 5
Results

Factor
No. of Spots
Delivered
Power Delivered
(mJ)
No. of Meds,
Post-op

360°

180°

Comments

103.8 +/- 13.291

103.14 +/- 19.268

P=0.7695

91.406 +/- 10.634

107.38 +/- 31.311

P<0.0001

16 (14.95%)
13 (12.15%)
28 (26.17%)
24 (22.43%)
26 (24.30%)

9 (8.57%)
19 (18.10%)
26 (24.76%)
30 (28.57%)
21 (20.00%)

P=0.3620

-0.009 +/- 0.5745

-0.114 +/- 0.7379

P=0.2499

-0.0164 +/- 0.1748

-0.0069 +/- 0.124

P=0.6455

19.299 +/- 4.1638

18.54 +/- 4.4992

P=0.1994

1 hour
6 weeks

17.028 +/- 6.5245
16.213 +/- 5.2025

19.093 +/- 5.9351
16.278 +/- 5.3927

P=0.0158
P=0.9285

3 months

15.747 +/- 4.5132

17.111 +/- 5.6739

P=0.0518

16.758 +/- 3.8582

16.75 +/- 4.7814

P=0.9896

6 weeks

16.198 +/- 5.1798

15.954 +/- 5.3396

P=0.7337

3 months

15.657 +/- 4.1674

16.574 +/- 5.4141

P=0.1648

Unadjusted
Adjusted

-3.552 +/- 3.6703
-3.4540

-1.492 +/- 4.1139
-1.5274

P<0.0001
P=0.0020

Unadjusted
Adjusted

-17.8 +/- 17.804
-17.8835

-7.456 +/- 23.436
-7.3684

P=0.0003
P=0.0016

0
1
2
3
≥4

Mean No. of
Med. Reduction
Post-op VA
Reduction
Pre-op IOP
(mmHg)
Post-op IOP
(mmHg)

Contra lateral
Pre-op IOP
Contra lateral
Post op IOP

∆ IOP at 3 mos.
(mmHg)
∆ IOP at 3 mos.
(percentage)

Table 5. Summary of treatment results. Change in IOP Adjusted values determined by regression
analysis. All values given +/- standard deviation. Abbreviations: VA, visual acuity, IOP, intra-ocular
pressure, ∆ IOP, change in intra-ocular pressure.

Pre-operative intra-ocular pressure was statistically equivalent for both treatment arms
with a mean IOP in the 360° group of 19.299 mmHg and 18.54 mmHg in the 180° group
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(P=0.1994). Pre-operative IOPs were also statistically equivalent in the contra lateral,
untreated eye with measurements of 16.758 mmHg and 16.75 mmHg in the 360° and 180°
groups, respectively (P=0.9896). One hour post-operatively, the mean IOP in the 360° group
was significantly lower than in the 180° group with measurements of 17.028 mmHg and
19.093 mmHg, respectively (P=0.0158). At the 6 week and 3 month time points the mean
IOPs were statistically equivalent (P=0.9285 and P=0.0518, respectively) for both treatment
arms (see figure 2).
Intra-Ocular Pressure Treated Eye
21

20

Intra-ocular Pressure mmHg

19

18
360
180
17

16

15

14
Pre-Op

1 hr.

6 wks.

3 mos.

Post-operative Time Point

Figure 2. Pressure curves of the treated eyes in the 180° and 360° treatment subgroups including pretreatment, one hour, six week and three month measurement values(mmHg). Pre-treatment values
were determined by taking the average of intraocular pressure readings from the day of treatment and
two visits prior to the day of treatment. The difference in intraocular pressures were only statistically
significant at the one hour post-treatment time point (P=0.1994, P=0.0158, P=0.9285, P=0.0518).
Error bars represent the 95% confidence intervals.
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In the contra lateral, untreated eye the mean IOPs were also statistically equivalent at
the 6 week and 3 month time points (P=0.7337, P=0.1648, respectively) for both treatment
arms (see figure 3).
Intra-Ocular Pressure Untreated Eye
21

20

Intra-ocular Pressure

19

18
360
180
17

16

15

14
Pre-Op

6 wks.

3 mos.

Post-operative Time Point

Figure 3. Pressure curves of the eyes contra lateral to the treated eyes in the 180° and 360° treatment
subgroups including pre-treatment, six week and three month measurement values (mmHg). Pretreatment values were determined by taking the average of intraocular pressure readings from the day of
treatment and two visits prior to the day of treatment. There were no statistically significant differences
in intraocular at any of the time points (P=0.9896, P=0.7337, P=0.1648). Error bars represent the 95%
confidence intervals.

While the measured IOPs were equivalent for both treatment arms at the 3 month
time point, the overall changes in IOP were not. The baseline-adjusted reduction in IOP for
the 360° group was 3.552 mmHg and 1.492 mmHg for the 180° group (P<0.0001). The
baseline-adjusted reductions in IOP in terms of percentage points were 17.8% and 7.456% in
the 360° and 180° groups, respectively (P=0.0003).
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Regression analyses were performed on three month IOP reductions in terms of
mmHg as well as percent change in order to adjust outcomes for differences in age, overall
power delivered, gender, type of glaucoma, presence of prior ALT and prostaglandin
treatment. In analysis of maximum likelihood estimates, prostaglandins were shown to have a
significant negative correlation with reduction of IOP (P=0.0305). The remaining factors were
not found to have significant correlations with IOP reduction. After the results were recalculated in the regression analyses taking into account these variables, the reduction in IOP
for the 360° group was 3.4541 mmHg and 1.5274 mmHg for the 180° group (P=0.0020). The
adjusted reductions in IOP in terms of percentage points were 17.8834% and 7.3684% in the
360° and 180° groups, respectively (P=0.0016).
Two different criteria were established to judge the success of each one of the
treatment protocols. One was a greater than 3 mmHg reduction in IOP and the other was a
greater than 20% reduction in IOP. The success rates for reduction of IOP greater than 3
mmHg at one hour were 55 and 25 (P<0.0001) for the 360° and 180° groups, respectively. At
6 weeks the rates were equivalent at 57 and 43 (P=0.0561). At 3 months the 360° group again
had a significantly better response rate with 65 patients successfully treated compared with 31
in the 180° group (P<0.0001). The 360° group had significantly better response rates at all
three time points for the greater than 20% reduction of IOP criteria. At the one hour time
point the success rates were 47 and 18 (P<0.0001), At 6 weeks they were 50 and 32 (P=0.016)
and at three months they were 55 and 23 (P<0.0001) for the 360° and 180° groups,
respectively. The results are graphically represented in figure 4.
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Table 6
Treatment Success Rates
>3mmHg
Responders

>20%
Responders

1 hour
6 weeks
3 months

55 (50.93%)
57 (52.78%)
65 (60.19%)

25 (23.15%)
43 (39.81%)
31 (28.70%)

P<0.0001
P=0.0561
P<0.0001

1 hour
6 weeks
3 months

47 (43.52%)
50 (46.30%)
55 (50.93%)

18 (16.67%)
32 (29.63%)
23 (21.30%)

P<0.0001
P=0.016
P<0.0001

Table 6. Treatment success rates for both >3mmHg and >20% IOP reduction criteria.
>3 mmHg IOP Reduction Success Rates
70

60

# of Successful Patients

50

40
360
180
30

20

10

0
1 hr.

6 wks.

3 mos.

Post-operative Time Point

Figure 4. Treatment success rates for >3 mmHg reduction in IOP. The 360° group had
significantly higher response rates at the 1 hour and three month time points (P>0.0001, P>0.0001) and
marginally significant at six weeks (P=0.0561).
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>20% IOP Reduction at 3 months
60

# of Successful Patients

50

40

360
180

30

20

10

0
1 hr.

6 wks.

3 mos.

Post-operative Time Point

Figure 5. Treatment success rates for >20% reduction in IOP. The 360° group had significantly higher
response rates at all three time points (P>0.0001, P=0.0160, P>0.0001).

Success rates at 3 months for the 3 mmHg criteria, broken down by presence or
absence of prior prostaglandin treatment and ALT, were also determined. These results are
displayed in table 7. Fifty-nine patients in the 360° group were on prostaglandins with a
success rate of 33 (55.93%) vs. 23 (26.74) for the 86 of the patients in the 180° group who
were on prostaglandins. This was statistically significant (P=0.0004). Forty-nine patients in
the 360° group were not on prostaglandins with a success rate of 32 (65.31%) vs. 8 (38.10%)
of the 21 patients in the 180° group who were not on prostaglandins. This was statistically
significant (P=0.0350).
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Eighteen patients in the 360° group had received prior ALT with a success rate of 9
(50.00%) vs. 11 (25.58%) of the 43 of the patients in the 180° group that had received prior
ALT. This was statistically significant (P=0.0639). Eighty-eight patients in the 360° group had
not received prior ALT with a success rate of 56 (63.64%) vs. 20 (30.77%) of the 65 the
patients in the 180° group who had not received prior ALT. This was statistically significant
(P<0.0001).
Table 7
Three month SLT success rates (>3mmHg) considering prostaglandin and prior ALT treatment

Factor

360°

180°

Comment

Success

33 (55.93%)

23 (26.74%)

P=0.0004

Success

32 (65.31%)
P=0.3218

8 (38.10%)
P=0.3039

P=0.0350

Success

9 (50.00%)

11 (25.58%)

P=0.0639

Success

56 (63.64%)
P=0.2791

20 (30.77%)
P=0.5596

P<0.0001

w/ Prostaglandins
w/o Prostaglandins
Subgroup analysis
w/ALT
w/o ALT
Subgroup analysis

Table 7. Three month success rates (>3mmHg) considering prostaglandin and prior ALT treatment.
Subgroup analyses compare success rates of patients on and off prostaglandins or with and without
prior ALT within treatment groups. Success rates were not significantly affected in either treatment
group irrespective of prostaglandins or prior ALT. Abbreviations: SLT, selective laser trabeculoplasty,
ALT, argon laser trabeculoplasty.

Subgroup analyses were conducted in order to determine the affect of prostaglandin
and ALT treatment on success rates for SLT within each of the treatment arms. In the 360°
group patients on prostaglandins had a success rate of 55.93% versus a rate of 65.31% for
those patients not receiving prostaglandins. This was not a statistically significant difference
(P=0.3218). In the 180° group patients on prostaglandins had a success rate of 26.74% versus
a rate of 38.10% for those patients not receiving prostaglandins. This was not a statistically
significant difference (P=0.3039). In the 360° group patients who had received prior ALT had
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a success rate of 50.00% versus a rate of 63.64% for those patients who had not. This was
not a statistically significant difference (P=0.2791). In the 180° group patients who had
received prior ALT had a success rate of 25.58% versus a rate of 74.42% for those patients
who had not. This was not a statistically significant difference (P=0.5596).
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CONCLUSIONS

Selective laser trabeculoplasty (SLT) is a relatively new treatment technique and the
optimal amount of power to be deliver and extent of trabecular meshwork to be treated are as
yet undetermined.

In order to further establish the optimal protocol for treatment of

glaucoma with SLT we conducted a retrospective chart review of 216 patients. Of these 216
subjects 108 received 100 spots over 180° while the other 108 received 100 spots over 360°.
Our results were similar to the findings of another study conducted by Rinke et al. (66) which
found a trend towards 360° being more efficacious than 180°. In that study the 180° degree
group had a 1.7 mmHg (8.3%) drop in IOP compared with the 1.49 mmHg (8.0%) IOP
reduction in our study. In the 360° group there was a 4.5 mmHg (20.7%) drop in IOP in the
Rinke et al. study while there was a 3.49 mmHg (18%) reduction in our study. While the trend
towards 360° being more efficacious did not reach statistical significance in the Rinke et al.
study, it did in ours. On the contrary to the Rinke study, another study by Nagar et al. (65)
found that 360° and 180° of SLT were equally effective. Despite this, this study still showed
the significance that different degrees of SLT application can make as they found that both
180° and 360° were more effective than 90°. A study by Chen et al. (55) showed that 90° and
180° of SLT had equivalent efficacies contradicting the significance of degree SLT treated
found in the above mentioned studies.
The exact mechanism by which SLT acts is unknown. All existing hypotheses that
attempt to describe this mechanism at least partially rely on the biological response to the
induced expression of cytokines after SLT. These mechanisms are the increased permeability
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of the endothelial cells in the TM and Schlemm’s canal (20), remodeling of the extracellular
matrix of the TM and repopulation of TM endothelial cells (5). All of these mechanisms
influence each other and the induction of cytokine expression plays a potential role in
modulating all of them. A potentially confounding variable in our study was the fact that the
180° group received prednisolone post-operatively. Steroids act by inhibiting phospholipase
A2 from producing arachidonic acid. This is the main substrate for both the cyclooxygenase
and lipooxygenase pathways which are responsible for generating inflammatory cytokines
thought to be responsible for the biological response to SLT that lowers IOP. Due to the
administration of steroids, the 180° group’s response to therapy may have been reduced. The
apparent difference in the efficacy between the two groups may, to a certain extent, reflect this
difference in post-operative treatment rather than the fundamental efficacy of the two
treatment protocols.
Another variable that may have affected the outcome between the two groups was the
density of the energy applied to the TM. The 180° group had 100 spots applied over one half
of the TM with a mean total energy of 107.4 mJ. This was nearly a three fold higher energy
density than that used in the study conducted by Kramer et al. (2) which described the
histological changes due to SLT application. In that study 50 spots were applied over 180°
with a total energy of about 40 mJ. The 360° group, on the other hand, received a mean total
of 45.703 mJ per 180° of TM, which was comparable to the energy delivered in the Kramer
paper. In the Kramer study post-treatment scanning electron microscopy showed minimal
mechanical disruption of the collagen scaffolding and trabecular beams with no evidence of
crater formation or coagulative damage in the TM. Transmission electron microscopy found
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that pigmented TM cells were selectively damaged and killed while leaving adjacent nonpigmented TM cells unharmed. While the lack of structural damage to the TM and selective
damaging of pigmented TM cells can be assumed for the 360° group due to similar SLT
protocols, this may not have been the case for the 180° group. This may account for the
poorer response of patients in the 180° treatment protocol.
There are other baseline factors that have been documented to affect the outcome of
SLT. One of these factors is prostaglandin treatment prior to SLT, which has been shown to
cause higher failure rate of treatment. This was reported in a paper by Song et al. although the
difference in outcomes between those treated and those untreated was not statistically
significant. In the present study we found a significant inverse relationship between
prostaglandin treatment and magnitude of IOP reduction.

Despite this, prostaglandin

treatment did not significantly affect SLT outcomes between the two groups according to the
two success criteria. Furthermore, it did not affect the frequency of SLT success within both
treatment groups during subgroup analyses. There were a greater number of patients in the
180° group that were on prostaglandins prior to SLT application. While this difference existed
as a potential confounding factor it was not shown to affect the overall outcome when
considered in the regression analysis. Baseline IOP and pseudophakic status are two further
factors that has been shown to affect outcome of SLT (45,50,68,69).

There were not

statistically significant differences in the baseline IOP or frequency of pseudophakia between
the two groups so any effect these factors may have had on the outcomes should have been
equivalent for the two groups.
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The limits of this study include the fact that it was conducted retrospectively, had a
brief follow-up period, was conducted by two different surgeons and the increased spot
density in the 180° group. There were also differences in the amount of patients on
prostaglandins, with prior ALT, type of glaucoma, gender and ages varied between the two
groups and total energy was greater in the 180° group. These factors were all considered when
conducting the regression analyses and were not found to have a significant effect on
outcomes.
In addition to the application of steroids administered post-operatively in one group
and not the other discussed above, medication regimens in general were managed postoperatively at the discretion of the performing surgeon. This leaves the possibility that the
change in IOP may not have only been effected by application of SLT. This was unlikely to
have affected the outcome greatly considering that both groups had a statistically equivalent
decrease in the number of medication they were taking post operatively. Another limitation is
the fact that patients that required an additional application of SLT during the 3 month followup period were not included in analyses. This precludes the ability to evaluate rates outright
treatment failure between the two groups.
The present study suggests that that 360° of SLT is more effective at lowering IOP
after a three month follow-up period. This adds to the body of evidence also suggesting that
greater degrees of SLT treatment are more efficacious. Further, prospective studies need to be
conducted in order to elucidate what the optimal degree of treatment is.
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